Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PBRM1-Dependent PBAF Targeting is Required for EMT and Metastasis in Breast Cancer.

bioRxiv : the preprint server for biology·2025
Same author

BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

Science advances·2024
Same author

MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer.

Molecular cancer research : MCR·2024
Same author

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.

Molecular cancer therapeutics·2023
Same author

Actin Cross-Linking Effector Domain of the <i>Vibrio vulnificus</i> F-Type MARTX Toxin Dominates Disease Progression During Intestinal Infection.

Infection and immunity·2022

Related Experiment Video

Updated: Jun 8, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.9K

ABBV-303 Is an NK-cell Engager Specific for c-Met-Expressing Tumors.

Jennifer D Stone1, Kamonwan Fish1, Devika Ashok2

  • 1Oncology Discovery Research, AbbVie Inc., North Chicago, Illinois.

Cancer Research
|October 28, 2025
PubMed
Summary
This summary is machine-generated.

Natural killer (NK) cell therapies offer safer "off the shelf" cancer treatment. ABBV-303, a novel c-Met targeted NK cell engager, effectively redirects NK cells to eliminate c-Met expressing tumors with enhanced safety.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.2K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Related Experiment Videos

Last Updated: Jun 8, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.9K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.2K
Assessment of Human Natural Killer Cell Events Driven by Fc&#947;RIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.9K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Natural killer (NK) cell therapies are promising
  • off the shelf
  • cancer treatments with improved safety profiles compared to T cell therapies.
  • The c-Met receptor tyrosine kinase is implicated in various solid tumors, making it a target for cancer therapy.

Purpose of the Study:

  • To develop and evaluate ABBV-303, a novel multispecific NK cell engager targeting c-Met.
  • To assess the efficacy and safety of ABBV-303 in redirecting NK cells and CD8+ T cells against c-Met expressing tumors.

Main Methods:

  • Development of ABBV-303, a trifunctional molecule engaging c-Met, NKG2D, and FcγRIIIa.
  • In vitro assessment of NK and CD8+ T cell activation and tumor cell killing.
  • In vivo efficacy studies in CD34-humanized, IL-15 transgenic NSG mice xenograft models.
  • Comparative analysis with a CD3 bispecific antibody.

Main Results:

  • ABBV-303 demonstrated potent sub-nanomolar redirected killing of c-Met+ tumor cells across various solid tumor types.
  • In vitro studies confirmed NK and CD8+ T cell activation and cytokine release upon ABBV-303 treatment.
  • In vivo studies showed significant anti-tumor activity of ABBV-303 against established xenografts.
  • ABBV-303 exhibited lower inflammatory cytokine induction and enhanced tolerance of normal cells compared to a CD3 bispecific.

Conclusions:

  • ABBV-303 is an effective NK cell engager for targeting c-Met expressing tumors.
  • The molecule demonstrates potent anti-tumor activity and an improved safety profile.
  • ABBV-303 holds promise as a next-generation cancer immunotherapy.